Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference newsletter

Ovarian Neoplasms

Free Subscription 05.10.2020 1 Ann Oncol 1 Br J Cancer 3 Clin Cancer Res 7 Gynecol Oncol 1 Int J Cancer 1 Oncogene

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. MILLER RE, Leary A, Scott CL, Serra V, et al
   ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
   Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
   PubMed         Abstract available
   
   

   
   Br J Cancer

2. KIM HS, Park SY, Park CY, Kim YT, et al
   A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
   Br J Cancer. 2020 Sep 30. pii: 10.1038/s41416-020-01098.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

3. ISHAK CA, De Carvalho DD
   DNA methylation profiling of premalignant lesions as a path to ovarian cancer early detection.
   Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-3331.
   PubMed         Abstract available
   
   
4. SOLIMAN PT, Westin SN, Iglesias DA, Fellman BM, et al
   Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study.
   Clin Cancer Res. 2019 Oct 18. pii: 1078-0432.CCR-19-0471.
   PubMed         Abstract available
   
   
5. MCCLOSKEY CW, Cook DP, Kelly BS, Azzi F, et al
   Metformin abrogates age-associated ovarian fibrosis.
   Clin Cancer Res. 2019 Oct 9. pii: 1078-0432.CCR-19-0603.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

6. MUSORO JZ, Coens C, Greimel E, King MT, et al
   Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
   Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
   PubMed         Abstract available
   
   
7. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
   Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
   Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
   PubMed         Abstract available
   
   
8. CHARO LM, Jou J, Binder P, Hohmann SF, et al
   Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
   Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
   PubMed         Abstract available
   
   
9. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
   Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
   Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
   PubMed         Abstract available
   
   
10. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    PubMed         Abstract available
    
    
11. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    PubMed         Abstract available
    
    
12. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    PubMed        
    
    

    
    Int J Cancer

13. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    PubMed         Abstract available
    
    

    
    Oncogene

14. XU Z, Li X, Li H, Nie C, et al
    Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01482.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: